The latest data point for Q1'26 shows ROE at -11.5%, ROA at -8.8%, and ROIC at -10.0%, indicating continued negative profitability metrics for RXRX, though all have improved from the deeper losses observed in prior quarters. Over the period from Q2'23 to Q1'26, ROE, ROA, and ROIC exhibit a volatile yet overall improving trend from initial lows around -16% to -21% in mid-2023, reaching their least negative levels in Q4'25 (ROE at -9.6%, ROA at -7.3%, ROIC at -8.0%) before a slight deterioration in Q1'26; notable inflection points include a sharp recovery in Q2'24 and Q4'25, suggesting gradual enhancements in operational efficiency despite persistent negative returns, with ROA consistently outperforming the other metrics. ROIC data is unavailable for Q2'25 and Q3'25, limiting full trend visibility in that interval.